Scope of the Study
Cancer treatment has a well focus on personalized medicine, leading to patient segmentation based on biomarker status. Major cancer types are lung, breast, colorectal (CRC), melanoma which become increasingly segmented, with each segment now being recognized as having specific treatment options and consequences. Oncology remains to be an area of active interest with a healthy pipeline of which 87% is a targeted therapy, several of the targeted therapies in development have an associated biomarker . Future oncology cost growth is expected to be in the range of 6% to 9%, annually, through 2021. The pipeline of oncology drugs in medical development has extended by 45% over the past ten years.
The market study is being classified by Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Others), by Application (Breast Cancer, Blood Cancer, Colorectal, Melanoma and Others) and major geographies with country level break-up.
Hoffmann-La Roche AG (Switzerland), Novartis International AG (Switzerland), Celgene Corporation (United States), Janssen Pharmaceutical (Belgium), Bristol-Myers Squibb (United States), Pfizer Inc. (United States), Merck & Co. (United States), Eli Lilly and Company (United States), AbbVie, Inc. (United States), AstraZeneca plc. (United Kingdom), Bayer AG (Germany) and Amgen Inc. (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Oncology Pharmaceuticals market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Oncology Pharmaceuticals market by Type, Application and Region.
On the basis of geography, the market of Oncology Pharmaceuticals has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Switzerland, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
- Rising Spending On Therapeutic and Supportive Care for Cancer
- Increase in Treatment Options That Have Helped To Lengthen Lives
- Rapid Uptake of Immuno-Oncology Drugs
- Adverse Effects Associated With the Use of Cancer Drugs
- Increasing Product Approvals by Regulatory Bodies for the Treatment of Various Cancers
- High Costs of Oncology Therapeutics and Complexity in Cancer Treatments
Market Leaders and their expansionary development strategies
On July 1, 2019 Novartis has announced that it has completed its acquisition of Xiidra, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.
On May 2, 2019- Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, has announced a precision medicine collaboration in oncology. Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. and July 2, 2019- Sandoz has announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK, which is recommended by ESMO as first-line treatment.
Key Target AudienceManufacturers of Oncology Drugs, Suppliers of Oncology Drugs, Wholesalers, Distributors and Retailers of Oncology Drugs, Healthcare Industry, Research Institutes and Governmental Bodies
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase